Juvenile Idiopathic Arthritis Clinical Trial
Official title:
Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis
The purpose of this study is to determine the optimal dosage of etanercept in patients treated for idiopathic juvenile arthritis
Etanercept, a fully human soluble tumor necrosis factor (TNF) receptor fusion protein, has been demonstrated to be safe and efficacious for the treatment of patients with polyarticular JIA. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be beneficial. It has been shown that the clinical response to two anti-TNFalpha biological agents (infliximab, adalimumab) closely follows the trough drug levels and the presence of antibodies directed against the drugs. This study was undertaken to investigate whether serologic monitoring of etanercept bioavailability and immunogenicity in individual patients with JIA would be useful in optimizing treatment regimens to improve efficacy and tolerability ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|